Proteinuria

Type: Keyphrase
Name: Proteinuria
First reported Oct 20 2014 - Updated Oct 20 2014 - 2 reports

Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011

Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)Additional GL-3 Data Further Validate Assay for Identifying Patients with Amenable MutationsCRANBURY, N.J., and SAN DIEGO, Oct. 19, 2014 ... [Published Virtual Strategy Magazine - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Patient Age and the Prognosis of Idiopathic Membranous Nephropathy

by Makoto Yamaguchi, Masahiko Ando, Ryohei Yamamoto, Shinichi Akiyama, Sawako Kato, Takayuki Katsuno, Tomoki Kosugi, Waichi Sato, Naotake Tsuboi, Yoshinari Yasuda, Masashi Mizuno, Yasuhiko Ito, Seiichi Matsuo, Shoichi MaruyamaBackgroundIdiopathic membranous ... [Published Plosone.org - Oct 20 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients

Source: Eur J Clin Nutr  |  Posted 2 days ago ; Nerbass F, Pecoits-Filho R, McIntyre N, McIntyre C, Taal M; European Journal of Clinical Nutrition (Oct 2014)Background/objectives:An increased risk of mortality and cardiovascular disease (CVD) is observed ... [Published Doctors Guide - Oct 18 2014]
Entities: Sodium, Risk, Proteinuria
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Effects of T-Type Calcium Channel Blockers on Renal Function and Aldosterone in Patients with Hypertension: A Systematic Review and Meta-Analysis

by Xue Li, Mao Sheng YangBackgroundHigh blood pressure can cause kidney damage, which can increase blood pressure, leading to a vicious cycle. It is not clear whether the protective effects of T-type calcium channel blockers (T-type CCBs) on renal function ... [Published Plosone.org - Oct 18 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Read About the New International Recommendations for Chronic Kidney Disease

What laboratorians need to know about the 2012 KDIGO Clinical Practice Guidelineby Graham Jones, MBBS, BSc(med), DPhil, FRCPA, FAACBChronic Kidney Disease (CKD) is a common clinical condition with significant adverse effects for patients. Since 2002, ... [Published Clincial Laboratory News - Oct 17 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Kidney Disease and Cognitive Function: African American-Diabetes Heart Study MIND

Aims: Albuminuria and reduced estimated glomerular filtration rate (eGFR) are linked with poorer cognitive performance in European-ancestry populations with advanced nephropathy; relationships in African Americans (AAs) with type 2 diabetes (T2D) are ... [Published Sexual Development - Oct 09 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders

by Bauke Schievink, Hiddo Lambers Heerspink, Hubert Leufkens, Dick De Zeeuw, Jarno HoekmanAimThere is discussion whether medicines can be authorized on the market based on evidence from surrogate endpoints. We assessed opinions of different stakeholders ... [Published Plosone.org - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Saxagliptin reverses proteinuria in type 2 diabetes

VIENNA – Patients with type 2 diabetes treated with the oral hypoglycemic saxagliptin (Onglyza) benefited from stabilization and, in some cases, reversal of urinary protein levels in a prespecified,... ... [Published Cardiology News - Sep 30 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Serendipity and Prof David Salant's odyssey to find a human autoantigen

:16 Internationally acclaimed expert, Professor David Salant, Professor of Medicine and Chief of Nephrology at Boston University Medical Center, delivered the AJ Orenstein Memorial Lecture at Wits University's Faculty of Health Sciences earlier this month. ... [Published Biz Community - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats

AbstractBackground/Aims: The search for new therapies providing cardiorenal protection in chronic kidney disease (CKD) has led to treatments that combine conventional renin-angiotensin-aldosterone-system inhibitors with other drugs that exhibit potential ... [Published Sexual Development - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 25 2014 - 1 reports

ALNYLAM PHARMACEUTICALS : Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development...

Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated DiseasesBy a News Reporter-Staff News Editor at Biotech Week ... [Published 4 Traders - Sep 24 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Alnylam announces pre-clinical results from membranous nephropathy trial

Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, has announced new pre-clinical results with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting complement component C5 in development for the treatment of primary membranous nephropathy, ... [Published Individual.com - Sep 22 2014]

Quotes

...They concluded: "These preliminary observations indicate the need for longer trials (particularly of primary prevention)"
Dr. Daniel Bichet, Full Professor and Section Head, Renal Function & Transport Physiology, University of Montreal, said, "Baseline proteinuria levels are among the most predictive indicators of disease prognosis and kidney function decline in Fabry patients. The data presented today show that when comparing patients with similar levels of proteinuria, patients treated with migalastat are more stable in their kidney function versus untreated patients. These results are very encouraging for migalastat as a treatment for Fabry patients with amenable mutations."
...Jay A Barth, Chief Medical Officer of Amicus TherapeuticsAmicus Therapeutics Inc. "The additional data on substrate reduction show that we can accurately identify patients who may benefit from migalastat. We look forward to meeting with regulatory agencies starting this quarter as we work to make migalastat available for all amenable Fabry patients as quickly as possible."
Patrice Milos, MD, chief executive officer of Claritas, explains, "This panel covers more genes than any other pediatric kidney disorder panel currently on the market. We expect to see a detection rate of over 60% in newborns diagnosed clinically with steroid-resistant Nephrotic Syndrome and an average detection rate for all age groups of around 30%. These ranges are well above the approximately 20% diagnostic yield for sequencing of NPHS2 alone, a gene that is often sequenced first when patients present with high levels of protein in the urine. Now clinical providers can look at many potential causative genes at once, instead of undertaking the inefficient and expensive process of sequential single gene testing."

More Content

All (78) | News (74) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Antiretroviral Therapies are Beneficial for HIV... [Published Infectious Diseases Society of America - 2 hours ago]
Handbook of Diabetes, 4th Ed., Excerpt #14: Dia... [Published Diabetes in Control - Oct 21 2014]
Patient Age and the Prognosis of Idiopathic Mem... [Published Plosone.org - Oct 20 2014]
Amicus Therapeutics Announces Additional Positi... [Published Virtual Strategy Magazine - Oct 20 2014]
Amicus Therapeutics Announces Additional Positi... [Published Market Pulse Navigator - Oct 20 2014]
Idera advances its second TLR therapeutic [Published Drug Discovery News - Oct 19 2014]
Claritas Genomics Launches Next Generation Sequ... [Published Advance for Administrators of the Laboratory - Oct 19 2014]
High sodium intake is associated with important... [Published Doctors Guide - Oct 18 2014]
Effects of T-Type Calcium Channel Blockers on R... [Published Plosone.org - Oct 18 2014]
Read About the New International Recommendation... [Published Clincial Laboratory News - Oct 17 2014]
Level of A1c Control and Its Predictors in T2DM [Published General Medicine eJournal - Oct 17 2014]
Early Onset Type 2 Diabetes: Clinical Impact an... [Published Theheart.org - Oct 17 2014]
Cognitive Impairment and Dementia in Type 2 Dia... [Published U.S.Pharmacist - Oct 16 2014]
"Method for Predicting Risk of Hypertension Ass... [Published 4 Traders - Oct 16 2014]
Cobicistat Safe for HIV-Positive Patients With ... [Published The Body PRO - Oct 15 2014]
Idera Pharmaceuticals Expands Pipeline by Initi... [Published Good Day Sacramento - Oct 14 2014]
Tenofovir Alafenamide vs. Tenofovir Disoproxil ... [Published General Medicine eJournal - Oct 13 2014]
Fatty Acid Oxidation Changes and the Correlatio... [Published Plosone.org - Oct 10 2014]
Kidney Disease and Cognitive Function: African ... [Published Sexual Development - Oct 09 2014]
Gene Expression Analysis in Tubule Interstitial... [Published Sexual Development - Oct 06 2014]
Acute Kidney Injury After CABG Versus PCI [Published General Medicine eJournal - Oct 06 2014]
“Our organs are sacred”: how we fail Aboriginal... [Published Crikey Media - Oct 04 2014]
Ardelyx announces positive results from phase 2... [Published PharmaBiz - Oct 04 2014]
A Gift Of Life [Published Mexico Ledger - Oct 03 2014]
Get Well Soon – wealth and fame gets a turn “on... [Published Crikey Media - Oct 02 2014]
September Clinical News and Product Briefs [Published Clinical Informatics News - Oct 02 2014]
Prevention of Immune Nephritis by the Small Mol... [Published Plosone.org - Oct 01 2014]
Thyroid cancer: additional new subgroup analyse... [Published Medical News Today - Oct 01 2014]
MAGI-2 and kidney barrier function [Medical Sci... [Published PNAS - Oct 01 2014]
The Use of Surrogate Endpoints in Regulating Me... [Published Plosone.org - Sep 30 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Hives after tetanus serum shot. Was it serum si... [Published HealthBoards - Sep 10 2014]
Hello,I recieved both tetanus toxoid and serum on June 1st. A week later I had hives and swelling in arms, my overall condition (judging subjectively) was not good, but blood and urine tests were not bad. 44 days after the shots I was able to test IgE, ...
Help me understand my tests? Don't look good [Published HealthBoards - Jul 20 2014]
Hey everybody just registered and I have a few questions regarding my urinalysis. Woke up one morning and noticed foamy urine which made me think huh? Looked it up and boom started freaking out because it points to kidneys. Being that I have hypertension ...
Proteinuria [Published HealthBoards - Jul 16 2014]
Hi,This is my first time here. I'm very worried because I'm 27 and a doctor found protein in my urine. I had this issue when I was 24 and it went away after 4 moths. I had a renal panel done and everything was fine. I got pregnant and my doctors of course ...
Proteinuria [Published HealthBoards - Jun 30 2014]
I had normal kidney function until last February. Not sure what happened, maybe a virus. I remember a really bad frontal headache and severe nausea and maybe some dizziness. But soon after, I had a routine visit to my chiropractor who takes my BP weekly ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.